The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry's ability to buy new molecules from biotechs based in China, along with a number of other ...

The biopharma job market remains challenging, based on BioSpace data. In August, job postings live on the website dropped 32% ...

New York City has seen increased life sciences employment during the past decade as public funding and key projects like ...

Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of ...

New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain.

Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a "smooth" approval process ...

Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will ...

The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window ...